Physician profile
Matthew K Johnson
NPI 1437312709
$2,874.53
in general payments reported to CMS, 2019-2025
25 companies · $551 in 2025
The $551 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $281 · 2021: $129 · 2022: $62.12 · 2023: $617 · 2024: $810 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941 · Education: $36.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.80 |
| Education | $36.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $434.69 | 2021-2024 | |
| Abbott Laboratories | $407.51 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $284.32 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.05 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $259.79 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $231.22 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Incyte Corporation | $127.34 | 2025 | |
| Medtronic, INC. | $117.68 | 2023-2024 | Intellis Adaptivestim |
| Allergan, INC. | $116.71 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $90.14 | 2019-2025 | Rexulti |
| Novo Nordisk INC | $79.50 | 2019-2023 | Rybelsus, Ozempic, Saxenda |
| Axsome Therapeutics, INC. | $62.80 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.54 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $48.11 | 2019-2023 | |
| Glaxosmithkline, LLC. | $47.85 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $35.57 | 2020 | |
| Amgen INC. | $34.74 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $31.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.57 | 2023 | Spravato |
| Spr Therapeutics, INC | $21.91 | 2025 | Sprint Pns System |
| Teva Pharmaceuticals USA, INC. | $19.18 | 2019 | |
| Kaleo, INC. | $17.62 | 2020 | |
| Xeris Pharmaceuticals, INC. | $17.24 | 2023 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $14.08 | 2020 | |
| Eisai INC. | $13.42 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.